Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Philip J. Stella"'
Autor:
Edith A. Perez, Wilma L. Lingle, Philip J. Stella, Jake B. Allred, Betsy LaPlant, Vivek Roy, Alvaro Moreno-Aspitia, Donald W. Northfelt, Timothy J. Hobday, Amylou C. Dueck, David Hillman, Kathleen Tenner, Kathleen A. Kitzmann, Monica M. Reinholz
PDF file - 180KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d9f98691e6d83ac72904ddf03c5c28
https://doi.org/10.1158/1078-0432.22444238.v1
https://doi.org/10.1158/1078-0432.22444238.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Purpose:In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1245c78b3812c0cf88ea25d3e6a63da1
https://doi.org/10.1158/1078-0432.c.6530607.v1
https://doi.org/10.1158/1078-0432.c.6530607.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183c50348f78b182ac2d0dfe83ec7809
https://doi.org/10.1158/1078-0432.22481040.v1
https://doi.org/10.1158/1078-0432.22481040.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Figure SF3 Comparisons of the expression of the NRG family of ERBB ligands, at the RNA level, between post-anti-EGFR metastatic biopsies collected upon enrollment into FC-7, and post-neratinib residual tumor tissue samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76dd9652d0b387d9b195e9248619d2c0
https://doi.org/10.1158/1078-0432.22481046
https://doi.org/10.1158/1078-0432.22481046
Autor:
Edith A. Perez, Wilma L. Lingle, Philip J. Stella, Jake B. Allred, Betsy LaPlant, Vivek Roy, Alvaro Moreno-Aspitia, Donald W. Northfelt, Timothy J. Hobday, Amylou C. Dueck, David Hillman, Kathleen Tenner, Kathleen A. Kitzmann, Monica M. Reinholz
Purpose: To investigate the associations between baseline and posttreatment circulating tumor cell (CTC) gene expression and outcome of patients enrolled in four North Central Cancer Treatment Group metastatic breast cancer (MBC) trials in which spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9072c6804b69d12d73499eacb38238
https://doi.org/10.1158/1078-0432.c.6520112.v1
https://doi.org/10.1158/1078-0432.c.6520112.v1
Autor:
Ashok Srinivasan, Carmen J. Allegra, Peter C. Lucas, Norman Wolmark, Jan H. Beumer, Brian F. Kiesel, Melanie Finnigan, Ying Wang, Huichen Feng, Corey Lipchik, Patrick G. Gavin, Rim S. Kim, Katherine L. Pogue-Geile, Fanny Piette, Ashwin R. Sama, Ding Wang, Philip J. Stella, James L. Wade, Thomas J. George, James J. Lee, Samuel A. Jacobs
Figure SF2: cfDNA mutational analysis cfDNA from plasma collected upon enrollment was analyzed for mutations with a 74-gene Guardant panel (1). Alterations were identified in 30 genes as shown in the figure. Patient IDs: Green=Stable Disease, Red=Pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceec9a46ce902eabcc48711ac200bfdb
https://doi.org/10.1158/1078-0432.22481049
https://doi.org/10.1158/1078-0432.22481049
Autor:
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag, Shaker R Dakhil, Philip J Stella, Douglas J Weckstein, Donald B Wender, Meredith Faggen, Tyler J Zemla, Erica N Heying, Samantha R Schuetz, Stephanie Noble, Jeffrey A Meyerhardt, Tanios Bekaii-Saab, Charles S Fuchs, Kimmie Ng
Publikováno v:
The Oncologist. 27:292-298
Background Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. Patients and Methods In this multicenter, randomized, double-blind, plac
Autor:
Ciara C O Sullivan, Jun He, Vera J Suman, Krishna R Kalari, Roberto A Leon-Ferre, Jose C Villasboas-Bisneto, Pratima Chalasani, Demet Gokalp Yasar, Daniel M Anderson, Philip J Stella, Anthony J Jaslowski, Susan H Tannenbaum, Angela Saverimuthu, Donald Northfelt, Alvaro Moreno-Aspitia, Jodi M Carter, Minetta C Liu, Liewei Wang, Zhenkun Lou, Matthew P Goetz
Publikováno v:
Cancer Research. 82:OT2-19
Background: Although major advances have been made in the treatment of HER2+ metastatic breast cancer (MBC), the goal of care remains largely palliative, therefore better treatments are needed. Given encouraging preclinical and clinical data, the com
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Autor:
Patricia A. Ganz, Hanna Bandos, Charles E. Geyer, André Robidoux, Alexander H. G. Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M. Brufsky, Louis Fehrenbacher, Ann W. Parsons, Patrick J. Ward, Louise Provencher, John T. Hamm, Philip J. Stella, Robert L. Carolla, Richard G. Margolese, Henry R. Shibata, Edith A. Perez, Norman Wolmark
Publikováno v:
Breast Cancer Res Treat
Breast cancer research and treatment, vol 192, iss 1
Breast cancer research and treatment, vol 192, iss 1
BackgroundThe NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in node-negative early-stage breast cancer. A sub-study within B-36, focusing on symp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc37978c6f5023778ffd6e619163ac4
https://europepmc.org/articles/PMC8979645/
https://europepmc.org/articles/PMC8979645/